The development of effective therapies for neuromuscular disorders is hampered by considerable challenges, including the abundance of skeletal muscle within the body and the multisystemic nature of many of these diseases. Here, Muntoni and Wood review recent advances in the development of novel therapies that target RNA, which are exemplified by three disorders: Duchenne muscular dystrophy, myotonic dystrophy and spinal muscular atrophy.
- Francesco Muntoni
- Matthew J. A. Wood